CeriBell (NASDAQ:CBLL) Receives $31.20 Consensus PT from Analysts

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $31.20.

A number of analysts have weighed in on the company. JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price target on the stock. William Blair began coverage on CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating for the company. Bank of America began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a "buy" rating and a $30.00 target price on the stock. Finally, Canaccord Genuity Group upped their price objective on shares of CeriBell from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th.

CeriBell Stock Down 0.2 %

Shares of CeriBell stock traded down $0.05 during trading hours on Friday, reaching $28.79. 67,941 shares of the company were exchanged, compared to its average volume of 206,575. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.